McKesson Past Earnings Performance
Past criteria checks 2/6
McKesson has been growing earnings at an average annual rate of 42.4%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 7.6% per year.
Key information
42.4%
Earnings growth rate
44.8%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 7.6% |
| Return on equity | n/a |
| Net Margin | 0.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture
Nov 14
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Nov 09McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Oct 09McKesson: The Correction Is Not Over
Sep 10McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing
Aug 22McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Revenue & Expenses Breakdown
How McKesson makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 330,187 | 2,536 | 8,552 | 0 |
| 30 Jun 24 | 313,751 | 2,959 | 8,113 | 0 |
| 31 Mar 24 | 308,951 | 3,002 | 8,010 | 0 |
| 31 Dec 23 | 301,506 | 2,998 | 7,919 | 0 |
| 30 Sep 23 | 291,098 | 3,487 | 7,972 | 0 |
| 30 Jun 23 | 284,040 | 3,755 | 7,881 | 0 |
| 31 Mar 23 | 276,711 | 3,563 | 7,980 | 0 |
| 31 Dec 22 | 273,903 | 3,146 | 8,258 | 0 |
| 30 Sep 22 | 272,027 | 2,061 | 8,438 | 0 |
| 30 Jun 22 | 268,446 | 1,396 | 8,702 | 0 |
| 31 Mar 22 | 263,966 | 1,119 | 8,937 | 0 |
| 31 Dec 21 | 257,006 | 1,415 | 8,918 | 0 |
| 30 Sep 21 | 250,991 | -4,804 | 8,926 | 0 |
| 30 Jun 21 | 245,223 | -4,494 | 8,919 | 0 |
| 31 Mar 21 | 238,228 | -4,538 | 8,791 | 0 |
| 31 Dec 20 | 237,621 | -4,189 | 8,696 | 0 |
| 30 Sep 20 | 234,194 | 2,228 | 8,875 | 0 |
| 30 Jun 20 | 231,002 | 922 | 8,864 | 0 |
| 31 Mar 20 | 231,051 | 906 | 8,907 | 0 |
| 31 Dec 19 | 224,945 | -905 | 9,641 | 71 |
| 30 Sep 19 | 221,981 | -626 | 9,160 | 71 |
| 30 Jun 19 | 217,440 | 601 | 8,642 | 71 |
| 31 Mar 19 | 214,319 | 33 | 8,437 | 0 |
| 31 Dec 18 | 213,518 | -319 | 8,362 | 125 |
| 30 Sep 18 | 210,927 | 113 | 8,197 | 125 |
| 30 Jun 18 | 209,913 | -384 | 8,300 | 125 |
| 31 Mar 18 | 208,357 | 62 | 8,138 | 125 |
| 31 Dec 17 | 205,442 | 4,805 | 7,464 | 341 |
| 30 Sep 17 | 201,955 | 4,539 | 7,503 | 341 |
| 30 Jun 17 | 199,851 | 4,846 | 7,317 | 341 |
| 31 Mar 17 | 198,533 | 5,194 | 7,447 | 341 |
| 31 Dec 16 | 196,498 | 2,051 | 7,149 | 392 |
| 30 Sep 16 | 194,267 | 2,044 | 7,264 | 392 |
| 30 Jun 16 | 193,071 | 2,359 | 7,283 | 392 |
| 31 Mar 16 | 190,884 | 2,290 | 7,379 | 392 |
| 31 Dec 15 | 189,131 | 2,237 | 7,573 | 392 |
| 30 Sep 15 | 187,716 | 2,090 | 7,342 | 392 |
| 30 Jun 15 | 183,115 | 1,950 | 7,781 | 392 |
| 31 Mar 15 | 179,045 | 1,775 | 7,901 | 392 |
| 31 Dec 14 | 171,952 | 1,780 | 7,323 | 457 |
| 30 Sep 14 | 159,804 | 1,462 | 6,932 | 457 |
| 30 Jun 14 | 148,629 | 1,402 | 6,143 | 457 |
| 31 Mar 14 | 137,392 | 1,419 | 5,388 | 457 |
| 31 Dec 13 | 130,076 | 1,278 | 4,675 | 433 |
Quality Earnings: MCK has high quality earnings.
Growing Profit Margin: MCK's current net profit margins (0.8%) are lower than last year (1.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MCK has become profitable over the past 5 years, growing earnings by 42.4% per year.
Accelerating Growth: MCK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MCK had negative earnings growth (-27.3%) over the past year, making it difficult to compare to the Healthcare industry average (10.2%).
Return on Equity
High ROE: MCK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.